Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

P B Jeppesen, R Gilroy, M Pertkiewicz, J P Allard, B Messing, S J O'Keefe

380 Citationer (Scopus)

Abstract

Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This 24-week placebo-controlled study evaluated the ability of teduglutide to reduce parenteral support in patients with SBS with intestinal failure.
OriginalsprogEngelsk
TidsskriftGut
Vol/bind60
Udgave nummer7
Sider (fra-til)902-14
Antal sider13
ISSN0017-5749
DOI
StatusUdgivet - 2011
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome'. Sammen danner de et unikt fingeraftryk.

Citationsformater